⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALXO News
ALX Oncology Holdings Inc. Common Stock
Form 8-K
sec.gov
ALXO
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ALXO
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
globenewswire.com
ALXO
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
globenewswire.com
ALXO
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
ALX Oncology Announces Pricing of Underwritten Offering
globenewswire.com
ALXO
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
globenewswire.com
ALXO
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ALXO
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
globenewswire.com
ALXO
Hootan Troy Farahmand: Leading With Purpose and Compassion in Modern Healthcare
accessnewswire.com
ALXO